Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies, CSF
Test Overview
Clinical Utility
Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbor MOG antibodies. Patients very rarely harbour both antibodies.
Method
Cell-based immunofluorescence assay (IFA)
Method Description
This specific and sensitive cell-based assay is based on transfected cells expressing the full-length human MOG as target antigen.
Result Included
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)
Aliases/Synonyms
Anti-MOG; MOG Antibodies
Specimen
Specimen Type
CSFVolume
Sample Volume
1 mL
Minimum Volume
0.5 mL
Collection & Handling
Handling Information
Store and send frozen.
Stability
| Ambient | Refrigerated | Frozen |
|---|---|---|
| 6 hours | 14 days | 60 days |
Performance & Interpretation
Turnaround Time
9 days
Results
-
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)Negative
Comment
Results of 1+ to 4+ indicate the presence of this autoantibody in increasing titers
Referral Location
Canada
Interface & Setup
HL7 Interface Codes
| Order Code | Result Name | Result Codes | Units |
|---|---|---|---|
| MOG CSF | Anti MOG (CSF) | 62784 |
Test Version
Last Updated
2023-11-15